Oncolys shares surged on news that sales of Telomelysin injection had begun. The announcement of its inclusion in the Nikkei 225 and moves in semiconductor-related stocks are driving the market.
Oncolys BioPharma shares surged after the start of sales of Telomelysin injection, a treatment for esophageal cancer, on 21 August was viewed as a catalyst. Buying emerged during the 11 a.m. hour, with the stock updating its post-listing high.
Reports that the stock could be newly included in the Nikkei 225 constituents drew investor attention to the interpretation of the TOPIX inclusion criteria and the expected announcement. There were also reports that a flash update related to this information had been disclosed.
KOKUSAI ELECTRIC formed a high price range following the decision to add it to the Nikkei 225. It is expected to be newly included from 1 October, and activity in other stocks has also responded.
Semiconductor-related stocks, led by Kioxia Holdings, were bid up amid indications of large buying at the open, while the SOX Index remained at a high level in the United States, supporting the market. Increased investment in semiconductor manufacturing equipment was viewed as a catalyst.